Hidden $5 AI Manufacturer Revealed

The company manufacturing Nvidia's AI servers trades under a secret name. AI revenue: $30B this year. Stock price: $5.

Alkermes Oral Drug Helps Patients Stay Awake In Mid-Stage Sleep Disorder Study

Vandana Singh
July 21, 2025

Alkermes plc (NASDAQ:ALKS) on Monday released topline results from the randomized double-blind treatment period of the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1).

Narcolepsy is a chronic neurological disorder that disrupts the body’s ability to regulate sleep-wake cycles. It’s characterized by excessive daytime sleepiness and sudden, uncontrollable sleep attacks.

Alixorexton, formerly ALKS 2680, is an investigational, oral orexin 2 receptor (OX2R) agonist in phase 2 development as a once-daily treatment for NT1, narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH).

Also Read: Harmony Biosciences Stock Falls On FDA Setback For Pitolisant In Sleeping Disorder

In Vibrance-1, alixorexton met the primary endpoint across all doses tested, demonstrating statistically significant, clinically meaningful, and dose-dependent improvements in wakefulness on the Maintenance of Wakefulness Test (MWT) from baseline compared to placebo.

In addition to achieving normative wakefulness across all dose groups on the MWT (mean sleep latency >20 minutes), once-daily alixorexton demonstrated robust and clinically meaningful improvements compared to placebo on patient-reported outcomes related to excessive daytime sleepiness and other key symptoms such as fatigue and cognition.

Alixorexton was generally well tolerated at all doses tested. These data support rapid initiation of a global phase 3 program of alixorexton in patients with NT1.

Key Secondary Endpoints

Epworth Sleepiness Scale (ESS): At all doses tested, alixorexton drove statistically significant and clinically meaningful improvements from baseline in excessive daytime sleepiness compared to placebo on the Epworth Sleepiness Scale at week six (p<0.0001 at all doses).

Weekly Cataplexy Rates (WCR): Alixorexton numerically improved weekly cataplexy rates across all doses compared to placebo at week six and achieved statistical significance at the 6 mg dose (p=0.005).

Alixorexton demonstrated consistent and clinically meaningful improvements across several patient-reported outcome measures of symptoms important to patients, including:

Narcolepsy Severity Scale (NSS): Across all doses tested, alixorexton demonstrated clinically meaningful improvements from baseline in narcolepsy symptom severity as compared to placebo at week six (p<0.001 at all doses).

British Columbia Cognitive Complaints Inventory (BC-CCI): Across all doses tested, alixorexton demonstrated clinically meaningful improvements from baseline in cognitive complaints compared to placebo at week six (p<0.0001 at all doses).

PROMIS (Patient-Reported Outcomes Measurement Information System)-Fatigue: Across all doses tested, alixorexton demonstrated clinically meaningful improvements from baseline in fatigue as compared to placebo at week six (p<0.01 at all doses).

Alixorexton was generally well tolerated across all doses tested in the randomized double-blind period of the Vibrance-1 study.

No treatment-emergent serious adverse events (TEAEs) were reported. Most TEAEs were mild to moderate in severity and generally consistent with the events observed across the Alixorexton phase 1 program in healthy volunteers and patients.

No treatment-related safety signals were observed in hepatic and renal parameters, vital signs, or ophthalmic exams.

Vibrance-2 and Vibrance-3, phase 2 studies evaluating the safety and efficacy of alixorexton in adults with NT2 and IH, respectively, are ongoing.

In April 2024, Alkermes revealed topline results from the narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) cohorts of a phase 1b, proof-of-concept study evaluating ALKS 2680 for narcolepsy

ALKS 2680 data demonstrated clinically meaningful and statistically significant improvements from baseline in mean sleep latency on the Maintenance of Wakefulness Test compared to placebo at all doses tested. 

Price Action: ALKS stock is trading lower by 7.24% to $27.11 at last check Monday.

Read Next:

  • China-Led Rally Sends Iron Ore Over $100 Despite Looming Oversupply

Photo via Shutterstock

Continue Reading...

Popular

Trump seeks to fire official overseeing jobs data after weak employment report

WASHINGTON (AP) — President Donald Trump on Friday called for the firing of the head of the agency that produces the monthly jobs figures after a report showed hiring and was much weaker in May and June than previously reported.

Marjorie Taylor Greene Increases These 2 Stocks In Portfolio, Including This AI Name Up Over 100% YTD

Marjorie Taylor Greene has bought stocks multiple times in 2025 and her recent disclosure adds to one of the stocks that drew the biggest red flags in 2025.

How to Hack a $1.3T Market - Ad

Forget concrete. The new foundation for real estate success is digital, and Pacaso leads the way. Their tech unlocks a $1.3T real estate market. They've already earned $110M+ in gross profits in their operating history and reserved the Nasdaq ticker PCSO.

'Superman' Flies Past $400 Million But Falters Overseas, While 'Jurassic World Rebirth' Charges Toward $650 Million In A Red-Hot Summer Box Office Battle

Warner Bros.' Superman crossed $400 million globally despite weak overseas performance, while Universal's Jurassic World Rebirth nears $650 million in a competitive summer box office season led by major franchise films.

Warren Buffett's 2005 Warning Echoes Louder As Social Security Faces $18,100 Benefit Cut By 2033, CRFB Warns

Social Security faces dire future if Congress doesn't act. Analysis warns of 24% cuts in 7 years and insolvency for Medicare. Warren Buffett raised concerns 20 years ago.

If You Missed Tesla, Here's Your "Second Chance"... - Ad

If you missed your shot at turning $1,000 into more than $18,000 when I recommended Tesla, you'll want to pay close attention. I'm 100% convinced Elon's "Agenda X" could make early investors rich. But you need to hurry, because Elon and Visa are moments away from launching.

Federal Reserve likely to stand pat on rates this week, deepening the gulf between Powell and Trump

WASHINGTON (AP) — The Federal Reserve is expected to leave its short-term interest rate unchanged on Wednesday for the fifth straight meeting, a move that will likely underscore between how Chair Jerome Powell and his chief critic, President Donald Trump, see the economy.

Europe's central bank to hold off on another rate cut until it knows how bad the tariff blow will be

FRANKFURT, Germany (AP) — The European Central Bank will likely hold off on making another interest rate cut Thursday, choosing to wait until it can measure the size of any economic blow from .

Back the Biotech Company Unlocking Mushroom Health Benefits for All - Ad

Functional mushrooms can boost mental, gut, and immune health-but people can't grow them at home. One company is making it easy with a patent-pending kitchen device. Think Nespresso, but for mushrooms. The functional mushroom market is projected to nearly double by 2030.

Coldplay's jumbotron captures — what exactly? The internet has its theories

LONDON (AP) — It started out as a routine bit of fun at a Coldplay concert: Lead singer Chris Martin asked the cameras to scan the crowd for his “Jumbotron Song,” when he sings a few lines about the people the camera lands on.

Russia insists on achieving Ukraine goals despite Trump's ultimatum

Russia is open to peace with Ukraine, but achieving its goals remains a priority, Kremlin spokesman Dmitry Peskov said Sunday, days after U.S. President to agree to a ceasefire or .

Tap Into the $65B 'Shroom Boom' - Ad

People are rapidly discovering how mushrooms can enhance brain function, gut health, immunity, and more. The only thing holding them back? A simple way to grow them. Hypha Labs built a compact countertop device to solve exactly that.

Intel CEO Says He's 'Making Hard But Necessary Decisions' As Chipmaker Announces Massive Layoffs, Project Cancellations

Intel is slashing 31% of its workforce and halting global expansion projects in a sweeping restructuring effort as it struggles to compete with AI chip leader Nvidia and regain its edge in the rapidly evolving semiconductor industry.

Bitcoin's 4-Year Cycle Is Dead, Researcher Says: Here's Why It Matters For XRP

The crypto market has changed, and experts say relying on the traditional 4-year halving cycle could leave investors poorly positioned in

$5 Stock Building Nvidia's AI Servers - Ad

Nuclear stocks gained 51% as energy vampires drain grids . $2B+ revenue, Big Tech pays rent . Massive power opportunity brewing.

Charles Schwab To Launch Bitcoin, Ethereum Trading Services

Charles Schwab (NYSE:SCHW), one of the largest brokerage firms in the United States, has confirmed plans to launch Bitcoin (CRYPTO: BTC) and Ethereum (CRYPTO:

If You Own Tesla Stock, This Might Change Everything - Ad

Jeff Brown, an early Tesla bull, warns of a strange "Tesla Glitch" uncovered by Wall Street legend Larry Benedict. This anomaly has preceded $25B-$100B swings in Tesla's value - and he's using it to anticipate moves without buying or shorting a single share.

Colbert jokes about 'cancel culture' and has a very pointed message for President Donald Trump

Stephen Colbert returned for his first full program after that CBS was canceling his “Late Show” with some supportive late-night guests, a joke about cancel culture and an extremely pointed remark directed at President Donald Trump.

Leaked Memo Reveals AI's Next Land Grab - Ad

The U.S. Department of the Interior's internal memo has leaked ... and the contents are shocking. A federally backed resource monetization plan may soon go live, and it could trigger a new gold rush into select energy and mineral stocks. Investing legend Whitney Tilson breaks it all down inside.

Nvidia-Supplier Taiwan Semiconductor On A Roll, Profit Explodes With Strong Margin Growth

Taiwan Semiconductor (TSM) reports strong Q2 results and expects continued growth in demand for advanced processor technologies, with revenue guidance of $31.8 billion to $33.0 billion for Q3.

FDA Submission Expected This Summer - Invest Before It Happens - Ad

This company is making heart disease easier to detect with AI. Their tech has officially been designated a "Breakthrough" by the FDA. You now have an opportunity to get in at a potential inflection point.

These 3 Dividend-Yielding Stocks Could Outperform As High Fed Rates Spark $4.9 Billion Inflows: Expert

Expert highlights the top high divided yielding stocks and funds that investors could consider to seize the opportunity amid high Fed rates.

Pony AI Stock Dips Despite Major Shanghai Robotaxi Permit

Shares of autonomous driving firm Pony AI are trading lower Tuesday. The company announced Monday it secured a permit for driverless robotaxi services in Shanghai.

Back This Medical AI Tech - Ad

You don't often find healthcare tech company valued at $4M. HeartSciences is an exception. With $75M invested, including R&D, clinical trials, and product development, their patented AI software is approaching FDA submission, a potential major inflection point.

Tesla Cybertruck Bet Not Paying Off? Ford, GM Outsell EV Giant

Elon Musk's dream of having a top-selling electric pickup may be a thing of the past as the Cybertruck continues to see declining demand.

Elon Musk Once Revealed How He Comes Up With 'Crazy Ideas' — And Gets Them Off The Ground Even When Funding Is Scarce

Elon Musk once explained that he turns ambitious ideas into reality by starting with low-cost software ventures, using first principles thinking, and combining insights across industries—even without major funding.

Hidden $5 AI Manufacturer Revealed - Ad

The company manufacturing Nvidia's AI servers trades under a secret name. AI revenue: $30B this year. Stock price: $5.

The beauty industry loves argan oil. But demand, and drought, are straining Morocco and its trees

SMIMOU, Morocco (AP) — Argan oil runs through your fingers like liquid gold — hydrating, luscious, and restorative. Prized worldwide as a miracle cosmetic, it’s more than that in Morocco. It’s a lifeline for rural women and a byproduct of a forest slowly buckling under the weight of growing demand.

How to Hack a $1.3T Market - Ad

Forget concrete. The new foundation for real estate success is digital, and Pacaso leads the way. Their tech unlocks a $1.3T real estate market. They've already earned $110M+ in gross profits in their operating history and reserved the Nasdaq ticker PCSO.

Circle CEO: Stablecoins Are Going Mainstream — Fast

Jeremy Allaire, CEO of Circle Internet Group, Inc. (NYSE:CRCL), is offering a compelling vision for the future of digital finance and the role of stablecoins in the global economy.

Trump-Backed DOJ Motion Seeks Release Of Jeffrey Epstein, Maxwell Grand Jury Transcripts

DOJ moves to unseal grand jury testimony related to Jeffrey Epstein and Ghislaine Maxwell following criticism over handling of documents.

If You Missed Tesla, Here's Your "Second Chance"... - Ad

If you missed your shot at turning $1,000 into more than $18,000 when I recommended Tesla, you'll want to pay close attention. I'm 100% convinced Elon's "Agenda X" could make early investors rich. But you need to hurry, because Elon and Visa are moments away from launching.

Can you ever expect privacy in public? Coldplay kiss camera saga tells us a lot about the answer

NEW YORK (AP) — When the landed on a couple who tried (but failed) to duck out of the spotlight, the internet immediately got to work.

Back the Biotech Company Unlocking Mushroom Health Benefits for All - Ad

Functional mushrooms can boost mental, gut, and immune health-but people can't grow them at home. One company is making it easy with a patent-pending kitchen device. Think Nespresso, but for mushrooms. The functional mushroom market is projected to nearly double by 2030.

What's Going On With Builders FirstSource Stock Today?

Builders FirstSource beat Q2 EPS but missed on sales, cut its FY25 outlook, and saw margins shrink, sending shares down over 3%.

Trending Now

Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.

Copyright technicaltrading.org
Privacy Policy | Terms of Service